TransMedics Group (NASDAQ:TMDX) Rating Lowered to Hold at Wall Street Zen

TransMedics Group (NASDAQ:TMDX) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

TMDX has been the topic of a number of other reports. Piper Sandler lifted their price objective on shares of TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday. JPMorgan Chase & Co. boosted their price target on shares of TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a report on Wednesday. Oppenheimer upped their price objective on shares of TransMedics Group from $150.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday. Canaccord Genuity Group lifted their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Finally, Morgan Stanley boosted their target price on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Six analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $150.67.

TransMedics Group Stock Up 7.9%

Shares of NASDAQ:TMDX opened at $145.26 on Friday. The business’s 50 day moving average is $133.80 and its 200 day moving average is $126.44. TransMedics Group has a 12-month low of $62.07 and a 12-month high of $156.00. The stock has a market cap of $4.98 billion, a price-to-earnings ratio of 29.64 and a beta of 2.06. The company has a quick ratio of 7.13, a current ratio of 7.14 and a debt-to-equity ratio of 1.06.

Insider Activity at TransMedics Group

In related news, Director David Weill sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the transaction, the director owned 12,134 shares in the company, valued at approximately $1,682,257.76. This represents a 29.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Gerardo Hernandez sold 920 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the sale, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at $2,103,235.68. This represents a 5.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Whittier Trust Co. of Nevada Inc. boosted its position in TransMedics Group by 981.0% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after purchasing an additional 206 shares during the period. Salomon & Ludwin LLC bought a new stake in shares of TransMedics Group in the third quarter valued at approximately $28,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of TransMedics Group during the 3rd quarter valued at approximately $29,000. Optiver Holding B.V. boosted its holdings in TransMedics Group by 248.1% in the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after buying an additional 191 shares during the period. Finally, Allworth Financial LP grew its stake in TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after buying an additional 113 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.